Pancreatic Cancer News and Research RSS Feed - Pancreatic Cancer News and Research

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
Combining sonoporation with chemotherapy drug may help improve pancreatic cancer treatment

Combining sonoporation with chemotherapy drug may help improve pancreatic cancer treatment

Researchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called "sonoporation" with the commercially-available chemotherapy compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed. [More]
Combining vitamin A with chemotherapy may offer promise for pancreatic cancer treatment

Combining vitamin A with chemotherapy may offer promise for pancreatic cancer treatment

Around 8,800 people in the UK are diagnosed with pancreatic cancer each year. It is known as the UK's deadliest cancer, with a survival rate of just 3 per cent. Chemotherapy and radiotherapy alone are relatively unsuccessful in treating the disease, and while surgery to remove the tumour offers the best chance of survival, most patients are diagnosed when the cancer has already spread to other organs. [More]
Multimodal therapy may improve survival of pancreatic cancer patients

Multimodal therapy may improve survival of pancreatic cancer patients

In roughly one-third of pancreatic cancer patients, tumors have grown around the pancreas to encompass critical blood vessels. Conventional wisdom has long held that surgery to remove the tumors is rarely an option, and life expectancies are usually measured in months. [More]
AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016. [More]
Simultaneous DNA, RNA and protein analysis to enhance cancer immunology studies: an interview with Dr Joseph Beechem

Simultaneous DNA, RNA and protein analysis to enhance cancer immunology studies: an interview with Dr Joseph Beechem

Cancer immunology is all about how your immune cells are going to fight and kill your tumor cells. If you look at the pure genetic code of a T-cell that's going to kill your tumor compared to the same cell that has been “put-to-sleep” (by the tumor), the pure genetic DNA content of those two cells are identical. [More]
Patient-oriented online health resources can impact clinical outcomes of pancreatic cancer patients

Patient-oriented online health resources can impact clinical outcomes of pancreatic cancer patients

The Internet has become a powerful and important resource for daily life. When patients receive a medical diagnosis, particularly a difficult one like pancreatic cancer, the web can be an essential information tool, helping to enable patients to have meaningful discussions with health care providers. However, new research from Beth Israel Deaconess Medical Center published today in JAMA Surgery suggests that online information about pancreatic cancer is often written at a prohibitively high reading level and lacks accuracy concerning alternative therapies. [More]
Controlling cholesterol metabolism could help reduce pancreatic cancer spread

Controlling cholesterol metabolism could help reduce pancreatic cancer spread

Researchers have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis, pointing to a potential new treatment using drugs previously developed for atherosclerosis. [More]
Study assesses effect of chemoradiotherapy on survival of locally advanced pancreatic cancer patients

Study assesses effect of chemoradiotherapy on survival of locally advanced pancreatic cancer patients

In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer. [More]
Study shows cancer cell death via necroptosis can drive pancreatic tumor growth

Study shows cancer cell death via necroptosis can drive pancreatic tumor growth

The most aggressive form of pancreatic cancer - often described as one of the hardest malignancies to diagnose and treat -- thrives in the presence of neighboring tumor cells undergoing a particular form of "orchestrated cell death." This is according to a major study recently published in the journal Nature. [More]
SI-2 molecule can inhibit tumor growth in breast cancer mouse model

SI-2 molecule can inhibit tumor growth in breast cancer mouse model

Cancer cells communicate with their environment through cell molecules that pass on signals to the inside of the cell. The signals help cancer cells multiply and migrate, spreading the disease. [More]
Specific oral microbiome linked to pancreatic cancer risk

Specific oral microbiome linked to pancreatic cancer risk

The presence of certain bacteria in the mouth may reveal increased risk for pancreatic cancer and enable earlier, more precise treatment. This is the main finding of a study led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center to be presented April 19 in New Orleans at the annual meeting of the American Association for Cancer Research. [More]
Researchers find mechanism behind pancreatic cancer cells' resistance to certain drugs

Researchers find mechanism behind pancreatic cancer cells' resistance to certain drugs

Pancreatic cancer is on track to become the second leading cause of cancer-related deaths by 2020. These statistics are due, in part, to pancreatic cancer's resistance to most targeted cancer therapies. Working with pancreatic cancer cells, researchers have now found a mechanism that could be responsible for the cancer's resistance to at least one targeted approach. [More]
Genetic modification of common virus gives extra weapon to kill cancer cells

Genetic modification of common virus gives extra weapon to kill cancer cells

A common flu virus could be used to overcome patients' resistance to certain cancer drugs -- and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London. [More]
Newly developed implantable device can deliver chemotherapy drugs directly to pancreatic tumors

Newly developed implantable device can deliver chemotherapy drugs directly to pancreatic tumors

Pancreatic cancer is the third leading cause of cancer deaths in the United States, in part because it is very difficult for chemotherapy drugs to reach the pancreas, which is located deep within the abdomen. [More]
New sensor 1 million times more sensitive than current methods developed to help detect cancers earlier

New sensor 1 million times more sensitive than current methods developed to help detect cancers earlier

Physicists and engineers at Case Western Reserve University have developed an optical sensor, based on nanostructured metamaterials, that's 1 million times more sensitive than the current best available--one capable of identifying a single lightweight molecule in a highly dilute solution. [More]
BIDMC investigators identify precise 5-gene classifier for discriminating early pancreatic cancer

BIDMC investigators identify precise 5-gene classifier for discriminating early pancreatic cancer

Pancreatic cancer, the fourth leading cause of cancer death in the United States, is often diagnosed at a late stage, when curative treatment is no longer possible. A team led by investigators at Beth Israel Deaconess Medical Center has now identified and validated an accurate 5-gene classifier for discriminating early pancreatic cancer from non-malignant tissue. [More]
Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

The second annual Kevin Rudi Superhero 5K Fun Run will start and end by the Memorial Stadium Field House in Las Cruces. Money raised for sarcoma research will benefit The University of New Mexico Comprehensive Cancer Center. [More]
Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Inactivation of protein-coding gene promotes liver tissue regeneration in mammals

Scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) report that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals. [More]
SLU researchers discover compound that disrupts fibrotic process

SLU researchers discover compound that disrupts fibrotic process

Saint Louis University researchers have found that a type of compound that disrupts the process that causes fibrosis (scarring) in the lungs and liver also shows promise in preventing and treating fibrosis in yet another organ, the pancreas. The research was conducted in an animal model. [More]
Neutralizing acidic tumor environment increases efficacy of immune-targeting cancer therapies

Neutralizing acidic tumor environment increases efficacy of immune-targeting cancer therapies

Cancer cells have the ability to grow in an acidic tumor environment that is detrimental to other cells, including immune cells. In a Cancer Research cover article published this week, Moffitt Cancer Center reported that neutralizing the acidic tumor environment increases the efficacy of several immune-targeting cancer therapies. [More]
Advertisement